Patent intelligence · US
US 8350021
Conserved HBV and HCV sequences useful for gene silencing
Conserved HBV and HCV sequences useful for gene silencing
Patent details — US 8350021
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 8, 2013
- Expiration
- Jan 3, 2033
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Claims
- 4
- CPC classes
- A61K, A61K38/00, A61K48/00, A61P
Quick answer
US 8350021 (Conserved HBV and HCV sequences useful for gene silencing) is held by Alnylam Pharmaceuticals, Inc.. Status: granted. Granted Jan 8, 2013. Expires Jan 3, 2033 (6 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K38/00, A61K48/00, A61P, A61P1/16, A61P31/00
More from Alnylam Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12416006
Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof
granted -
US 12404508
Ketohexokinase (KHK) iRNA compositions and methods of use thereof
granted -
US 12397013
Extrahepatic delivery
granted -
US 12385043
Modified double-stranded RNA agents
granted -
US 12385044
Modified double-stranded RNA agents
granted -
US 12378553
Modified double-stranded RNA agents
granted -
US 12364762
Biodegradable lipids for the delivery of active agents
granted -
US 12350338
Biodegradable lipids for the delivery of active agents
granted
Frequently asked questions
What is US patent 8350021?
US 8350021 (Conserved HBV and HCV sequences useful for gene silencing) is held by Alnylam Pharmaceuticals, Inc.. Status: granted. Granted Jan 8, 2013. Expires Jan 3, 2033 (6 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8350021?
Alnylam Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 379 pharmaceutical patents for this assignee.
When does US 8350021 expire?
Our index shows an expiration date of Jan 3, 2033 (6 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.